Veeva Systems vs 22nd Century Group Inc — how do they compare? Veeva Systems trades at $296.13 (market cap $46.12B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: Veeva Systems is far larger — about 74187.3× 22nd Century Group Inc's market cap, and Veeva Systems is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Veeva Systems for 6 Days and 22nd Century Group Inc for 32 Days on average.
| VEEV | XXII | |
|---|---|---|
Market Cap | $46.12B | $621.67K |
Volume | 921,537 | 45,625 |
Sector | Technology | Consumer Staples |
52-Week High | $299.10 | $483.00 |
52-Week Low | $151.43 | $0.80 |
Typical Hold Time | 6 Days | 32 Days |
Enterprise Value | $39.03B | -$3.69M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Veeva Systems provides cloud software, data, and services for the life sciences industry. Its applications support functions across clinical research, regulatory operations, quality, safety, and commercial teams.
Read more on VEEV →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →